Biogen Bolsters Rare Disease Portfolio with $5.6 Billion Acquisition of Apellis

Apr 01, 2026 11:36 UTC

BIIB, APPL, ^GSPC

Short term

Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, enhancing its focus on rare diseases. The deal is expected to expand Biogen's therapeutic pipeline and strengthen its position in the biotech sector.

Biogen acquires Apellis for $5.6 billion in an all-cash deal.
The acquisition targets Apellis's pipeline in rare diseases, particularly complement biology.
The deal is expected to close in the second half of 2026.
Apellis shareholders will receive $45.50 per share in cash.
The transaction aligns with broader biotech consolidation trends.
Biogen aims to strengthen its rare disease therapeutic focus through this acquisition.

Biogen Inc. (BIIB) has announced a $5.6 billion acquisition of Apellis Pharmaceuticals (APPL), marking a significant move to bolster its rare disease portfolio. The all-cash deal, expected to close in the second half of 2026, aims to accelerate Biogen's strategic focus on therapies for rare and complex conditions. Apellis, known for its work in complement biology, brings a pipeline of investigational drugs that align with Biogen's long-term vision. The acquisition reflects a broader trend in the biotech sector, where companies are increasingly consolidating to strengthen their R&D capabilities and diversify their product offerings. With the U.S. healthcare market showing sustained demand for innovative treatments, Biogen's move could influence investor perceptions of M&A activity in the industry. The transaction is also likely to impact Apellis shareholders, who will receive $45.50 per share in cash under the agreement.